8-K

                        UNITED STATES
             SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549


                          FORM 8-K



                       CURRENT REPORT
           PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

 Date of Report (Date of earliest event reported):  November 18, 2003


                   Global Life Sciences, Inc.
              ------------------------------------
   (Exact Name of Registrant as Specified in Its Charter)

                           Nevada
                   -----------------------
       (State or other jurisdiction of incorporation)


          000-33333                          37-9374101
       ---------------                 -----------------------
   (Commission File Number)       (I.R.S. Employer Identification No.)


 2020 Main Street, Suite 600, Irvine, California            92614
- -------------------------------------------------          -------
     (Address of Principal Executive Offices)             (Zip Code)


                        949-223-7103
                --------------------------
   (Registrant's Telephone Number, including area code)


                       Too Gourmet, Inc.
             ----------------------------------
 (Former Name or Former Address, if Changed Since Last Report)






                            - 1 -






Item 5.   Other Events.

     We issued a press release on November 18, 2003, in which we
announced the following:

       *  We changed our name from "Too Gourmet, Inc." to "Global
          Life Sciences, Inc.," such name change is effective as of
          November 18, 2003;

       *  Our trading symbol has been changed to "GBLS" effective
          as of the opening of the markets on Wednesday, November 19,
          2003; and

       *  Our new Cusip number is 379374 10 1.


Item 7.   Financial Statements and Exhibits

a.   Financial Statements

     None.

b.   Pro forma Financial Information

     None.

c.   Exhibits.

99.1 Press Release by Global Life Sciences, Inc., dated November 18,
     2003, concerning the change of name, trading symbol and Cusip
     number.






                            - 2 -






                         SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                         GLOBAL LIFE SCIENCES, INC.


November 18, 2003             By:  /s/ Harrysen Mittler
                                  -----------------------
                              Harrysen Mittler
                              Chief Financial Officer






































                            - 3 -









Exhibit Index.

99.1  Press Release by Global Life Sciences, Inc., dated November 18,
      2003, concerning the change of name, trading symbol and Cusip
      number.






































                            - 4 -

EX-99

   TOO GOURMET, INC. CHANGES NAME, TRADING SYMBOL, AND CUSIP
                           NUMBER

Irvine, California November 18, 2003:  Global Life Sciences,
Inc.,-OTC: GBLS (formerly known as Too Gourmet, Inc. (TGOU) today
announced that it has changed its name to "Global Life Sciences,
Inc." in connection with its acquisition of Internationale
Fachklinik, a German medical laboratory and service provider.
The name change is effective Tuesday, November 18, 2003.  In
addition, the company announced that, effective at the opening of
the markets on Wednesday, November 19, 2003, the company's new
trading symbol is "GBLS" and its new Cusip number is "379374 10 1."

About Global Life Sciences, Inc.:

Global Life Sciences, Inc. owns and operates a medical laboratory
specializing in the research, analysis, and in vitro diagnosis of
live biopsy tissue samples for allergic, immunological, and
environmentally related disorders. In order to improve the
quality of test results, Prof. Reimann, the company's Chairman,
Chief Executive Officer and President, developed and patented a
unique device known as a "Tabox", which enables the precise
analysis of the effects of allergens and toxins on the human body
in an in vitro environment.

Currently, the company operates a total of 28 inter-clinic Tabox
systems as proprietary devices, which are available to
practitioners, clinics and other medical customers on a fee-for-
service basis. The company anticipates the production and use of
up to 100 Tabox systems by its medical customers by the end of
the third quarter 2004. In addition, new labs, research
facilities and integrated out-patient clinics are currently
projected to be established in Zurich (Switzerland) and Berlin
(Germany) during 2004 and 2005.

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements.  Certain
information included in this press release contains statements
that are forward-looking, such as statements related to the
future anticipated direction of the industry, plans for future
expansion, various business development activities, planned
capital expenditures, future funding sources, anticipated sales
growth, and potential contracts.  Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future and,
accordingly, such results may differ from those expressed in any
forward-looking statements made by, or on behalf of Too Gourmet,
Inc.  These risks and uncertainties include, but are not limited
to, those relating to development and expansion activities,
dependence on existing management, financing activities, and
domestic and global economic conditions.


Investor Contact:
Global Life Sciences, Inc.
Attention:  c/o  R. Katz
Phone:  949-223-7103


Business Contact:
Global Life Sciences, Inc.
Attention:  Prof. Dr. Reimann
Fax:  +49-4503-707532